62 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Jan 2029
Next term end
19
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2029 · High confidence
Also notable
Ends Nov 2030 · High confidence
Also notable
Ends Jul 2031 · High confidence
Steroidal Compositions
US 11,304,960
Cited by 68 later US patents, top 1% of utility patents granted in 2022 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
High-Strength Testosterone Undecanoate Compositions
US 9,034,858
The most cited patent in this portfolio, cited by 92 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2030.
17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods
US 8,951,996
Cited by 90 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for High-Strength Testosterone Undecanoate Compositions (US 9,034,858) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
- 1 fee due Dec 13, 2026The maintenance fee for Oral Testosterone Non-Undecanoate Therapy (US 11,672,807) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Jan 25, 2027The maintenance fee for (17-ß)-3-Oxoandrost-4-EN-17YL Tridecanoate Compositions and Methods of Their Preparation and Use (US 11,707,467) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Jun 8, 2027The maintenance fee for High-Strength Testosterone Undecanoate Compositions (US 9,205,057) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Bioavailable Solid State (17-Beta)-Hydroxy-4-Androsten-3-One Esters (US 11,872,235) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 1 fee due Aug 18, 2027The maintenance fee for Testosterone Undecanoate Compositions (US 10,561,615) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate Therapy (US 11,931,367) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Oral Allopregnanolone Compositions and Methods of Use (US 11,969,434) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
The 5 largest of its 19 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| High-Strength Testosterone Undecanoate Compositions | 12 in force | to Nov 2030 |
| Compositions and Methods for Treating Central Nervous System Disorders | 8 in force | to Dec 2042 |
| 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods | 7 in force | to Jul 2031 |
| Liver Disease | 5 in force | to Sep 2041 |
| Oral Testosterone Tridecanoate Therapy | 5 in force | to Sep 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,778,922 | Steroidal Compositions In force · High confidence | In force | High confidence | |
| US 8,865,695 | Steroidal Compositions In force · High confidence | In force | High confidence | |
| US 11,052,096 | Steroidal Compositions In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 11,304,960 | Steroidal Compositions In force · High confidence | In force | High confidence | |
| US 9,375,437 | Progesterone Containing Oral Dosage Forms and Kits In force · High confidence | In force | High confidence | |
| US 9,034,858 | High-Strength Testosterone Undecanoate Compositions In force · High confidence | In force | High confidence | |
| US 9,205,057 | High-Strength Testosterone Undecanoate Compositions In force · High confidence | In force | High confidence | |
| US 9,358,241 | High-Strength Testosterone Undecanoate Compositions In force · High confidence | In force | High confidence | |
| US 9,480,690 | High-Strength Testosterone Undecanoate Compositions In force · Medium confidence | In force | Medium confidence | |
| US 9,943,527 | High-Strength Testosterone Undecanoate Compositions In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 62: 10 patents ended · 10 applications pending · 100 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.